EUVIMEDEUVIMED entdecken
Multizentrische Studie

Ranolazine in Chronic Total Occlusion Percutaneous Coronary Intervention

Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini und 15 weitere

Journal of Invasive Cardiology · 2024

DOI: 10.25270/jic/24.00059 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Invasive Cardiology, 2024. Verfasst von Michaella Alexandrou und 26 weiteren Autor:innen. Beteiligte Einrichtung: Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Ranolazine, Percutaneous Coronary Intervention, Coronary Occlusion, Registries.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanolazinePercutaneous Coronary InterventionCoronary OcclusionRegistriesHumansMaleFemaleAgedMiddle AgedChronic DiseaseTreatment OutcomeCoronary AngiographyRetrospective Studies

Stichwörter der Autor:innen

CTO-PCIchronic total occlusioncoronary artery diseasepercutaneous coronary interventionranolazine

Substanzen

Ranolazine

Autor:innen und Institutionen

  • Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • Texas Health Presbyterian Hospital, Dallas, Texas, USA; Baylor Scott and White Heart and Vascular Hospital, Dallas, Texas, USA.
  • University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA.
  • Henry Ford Cardiovascular Division, Detroit, Michigan, USA.
  • WellSpan York Hospital, York, Pennsylvania, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.

Zitieren

APA

Alexandrou, M., Mutlu, D., Rempakos, A., Al Ogaili, A., Choi, J. W., Poommipanit, P., Alaswad, K., Basir, M. B., Davies, R., Jaffer, F. A., Dattilo, P., Azzalini, L., Aygul, N., Reddy, N., Jefferson, B. K., Gorgulu, S., Khatri, J. J., Young, L. D., Krestyaninov, O., …, & Brilakis, E. S. (2024). Ranolazine in Chronic Total Occlusion Percutaneous Coronary Intervention. Journal of Invasive Cardiology. https://doi.org/10.25270/jic/24.00059

Vancouver

Alexandrou M, Mutlu D, Rempakos A, Al Ogaili A, Choi JW, Poommipanit P, et al. Ranolazine in Chronic Total Occlusion Percutaneous Coronary Intervention. Journal of Invasive Cardiology. 2024. doi:10.25270/jic/24.00059

BibTeX
@article{Alexandrou2024,
  author = {Alexandrou, Michaella and Mutlu, Deniz and Rempakos, Athanasios and Al Ogaili, Ahmed and Choi, James W and Poommipanit, Paul and Alaswad, Khaldoon and Basir, Mir Babar and Davies, Rhian and Jaffer, Farouc A and Dattilo, Phil and Azzalini, Lorenzo and Aygul, Nazif and Reddy, Niranjan and Jefferson, Brian K and Gorgulu, Sevket and Khatri, Jaikirshan J and Young, Laura D and Krestyaninov, Oleg and Khelimskii, Dmitrii and Frizzell, Jarrod and Elbarouni, Basem and Rangan, Bavana V and Mastrodemos, Olga C and Burke, M Nicholas and Sandoval, Yader and Brilakis, Emmanouil S},
  title = {Ranolazine in Chronic Total Occlusion Percutaneous Coronary Intervention},
  journal = {Journal of Invasive Cardiology},
  year = {2024},
  doi = {10.25270/jic/24.00059}
}
Kostenlos starten →